Results 201 to 210 of about 8,771 (219)

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2021
Kristian Reich, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
Filip E Van Den Bosch, Denis Poddubnyy, Walter P Maksymowych   +2 more
exaly  

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

New England Journal of Medicine, 2021
Iain B Mcinnes, Jaclyn K Anderson, Marina Magrey   +2 more
exaly  

Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease

New England Journal of Medicine, 2023
Laurent Peyrin-Biroulet, Remo Panaccione, Hiroshi Nakase   +2 more
exaly  

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

New England Journal of Medicine, 2021
David T Felson
exaly  

Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience

Clinical Gastroenterology and Hepatology, 2023
David T Rubin
exaly  

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

New England Journal of Medicine, 2020
Andrea Rubbert-Roth, Jeffrey Enejosa, Boulos Haraoui   +2 more
exaly  

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Journal of Allergy and Clinical Immunology, 2023
E Guttman-Yassky, Ka Papp, Stephan Weidinger   +2 more
exaly  

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Lancet, The, 2019
Paul Emery, William F C Rigby, Yoshiya Tanaka   +2 more
exaly  

Upadacitinib

Reactions Weekly, 2022
openaire   +2 more sources